PFE Price Prediction Next Week
Analysis and Insights
News Sentiment and Recent Developments:
Pfizer (PFE) has been in the news recently for several positive developments. The company's CEO, Albert Bourla, emphasized that the stock is undervalued with significant upside potential. Additionally, Pfizer received a "Buy" rating from Jefferies with a price target of $33.00, further reinforcing positive sentiment. The company also announced a dividend increase, maintaining its attractive 6.58% dividend yield.
Technical Analysis:
The technical indicators for PFE suggest a neutral to slightly bullish outlook. The Relative Strength Index (RSI) is at 52.36, indicating the stock is not overbought or oversold. The MACD is slightly positive, suggesting some upward momentum. Fibonacci levels show resistance at $27.35 and support at $25.19, with the current price trading near the pivot point of $26.27.
Price Prediction and Recommendation:
Based on the analysis, Pfizer's stock is expected to trade near the resistance level of $27.35 in the next trading week. The combination of positive news sentiment, attractive valuation, and stable technical indicators supports a bullish outlook.
Predicted Price for Next Trading Week: $27.35
Recommendation: Buy
PFE Similar Chart Price Prediction
The price of PFE is predicted to go up 9.24%, based on the high correlation periods with EMX. The similarity of these two price pattern on the periods is 90.81%.
PFE
EMX
Up: 9.24%Similarity: 90.81%
PFE Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
PFE Price Forecast($)
Potential Return(%)
2025
26.730
0.530
2026
29.000
9.720
2027
30.000
13.510
2028
35.000
32.430
2029
15.000
-43.250
2030
35.000
32.430
What is PFE stock price prediction 2025 ?
What is PFE stock price prediction 2026 ?
What is PFE stock price prediction 2027 ?
What is PFE stock price prediction 2028 ?
What is PFE stock price prediction 2029 ?
What is PFE stock price prediction 2030 ?
PFE Revenue Forecast
PFE EPS Forecast
PFE FAQs
What is PFE revenue forecast for next quarter？
What is PFE eps forecast for next quarter？
PFE VS S&P500
Pfizer's pipeline productivity is improving with several successful recent drug launches. In particular, cardiovascular drug Vyndaqel is a potential game-changer in the rare-disease arena.
Pfizer's strong success in developing a COVID-19 vaccine and treatment is yielding a massive cash windfall.
Pfizer's decision to divest its off-patent division should result in a faster-growing, innovative company.
PFE Analyst's Forecast
Colin Bristow
UBS
Hold
2025-01-08
Price Target
$31 → $29
Upside
+7.97%
UBS lowered the firm's price target on Pfizer to $29 from $31 and keeps a Neutral rating on the shares as part of a broader note on the U.S. Pharmaceuticals and Biotechnology industry. The firm believes BioPharma will find it difficult to outperform against a more uncertain macro backdrop in the short-term, and thinks President-elect Trump will be capable of enacting significant legislative change, and that unpredictability is expected to cast a shadow over the space, the analyst tells investors in a research note. There will be continued uncertainty in the space until there is more clarity on Trump's changes, UBS says.
Tim Anderson
B of A Securities
Hold
2024-12-10
Price Target
$29
Upside
+13.41%
Alexandria Hammond
Wolfe Research
Sell
2024-11-15
Price Target
$25
Upside
+0.81%
